GlassScriptPhysician profile
James W Loveless
NPI 1689729550
$1,598.78
in general payments reported to CMS, 2019-2025
22 companies · $320 in 2025
The $320 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $84.47 · 2021: $220 · 2022: $272 · 2023: $164 · 2024: $225 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $405.60 | 2019-2025 | |
| Janssen Biotech, INC. | $163.00 | 2019-2022 | |
| Galderma Laboratories, L.P. | $123.66 | 2019-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $117.78 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Merz North America, INC. | $96.06 | 2019-2025 | |
| Pfizer INC. | $82.94 | 2019-2025 | |
| Amgen INC. | $80.48 | 2023-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $69.41 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $62.36 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $60.41 | 2019-2024 | |
| Allergan, INC. | $56.20 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $45.93 | 2024 | Zoryve |
| Ucb, INC. | $43.39 | 2019-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.71 | 2019-2024 | Cabtreo |
| Merck Sharp & Dohme LLC | $29.52 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $24.39 | 2023 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.14 | 2023 | Spevigo |
| Genzyme Corporation | $18.97 | 2019 | |
| Genentech USA, INC. | $16.04 | 2019 | |
| Dusa Pharmaceuticals, INC. | $15.62 | 2019 | |
| Biofrontera INC. | $13.66 | 2022 | |
| Incyte Corporation | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Loveless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.